2 ; 1 ; in Month : June (2021) Article No : ujrnm-v2-1004
Ernesto Maranzano, Fabio Trippa, Paola Anselmo, Fa

Abstract
“Oligometastatic” disease (OMD) has been proposed as an intermediate state between localised and widespread systemic disease [1]. In OMD patients with different tumor types/histologies, early published studies show improved clinical outcome when radical local therapy as surgery or metastasis-directed radiotherapy (MDRT) are administered [2-6]. Unfortunately, neither OMD specific biomarkers nor prospectively validated prognostic scoring systems yet exist so it remains impossible to identify patients with truly limited metastatic capacity, who might really benefit from such a radical approach [7]. The current definition of oligometastatic status is based solely on the number of metastases (less than 3-5) on high resolution imaging findings. Therefore, a PET/CT, contrast-enhanced chest/abdominal and pelvis CT scans, and/or MRI of brain or spine are necessary for case by case diagnostic evaluation [2-6].

Full Text Attachment

Views : 8      Downloads : 1

RSS